Clinical Trial: Testing Already FDA-Approved Drugs for Specific Gene Abnormality in Advanced Stage Cancers

0

What if cancer wan’t defined by it’s location in the body? Whether it was found in the liver, kidney, lung or blood, what if a specific genetic mutation caused the cancerous cells to grow? A new study is being sponsored by the American Society of Clinical Oncology (ASCO) called TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer. 

The study is being done in collaboration with seven pharmaceutical companies (AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme Corp., Pfizer) with up to 16 different drugs.

Patients with  Non-Hodgkins Lymphoma, Non-Hodgkin and Multiple Myeloma and Advanced Solid Tumors will be included in the study which will be open at many trial sites. Patients will be tested for their disease genetics and will then be separated into groups with the same genetic mutations. Each group will receive a drug that specifically targets those mutations.

Group 1 (VEGFR)

Participants receive axitinib – dosage, frequency and duration per label VEGFR mutation, amplification or overexpression)
Drug: Axitinib

Other Name: Inlyta

( Tyrosine Kinase (TK) Inhibitor )
Group 2 (Bcr-abl, SRC, LYN, LCK)

Participants receive bosutinib- dosage, frequency and duration per label Bcr-abl, SRC, LYN, LCK mutations
Drug: Bosutinib

Other Name: Bosulif
( Tyrosine Kinase (TK) Inhibitor )
Group 3 (ALK, ROS1, MET)

Participants receive crizotinib – dosage, frequency and duration per label ALK, ROS1, MET mutations
Drug: Crizotinib

Other Name: Xalkori
Group 4 (CDKN2A/p16, CDK4, CDK6)

Participants receive palbociclib – dosage, frequency and duration per label CDKN2A/p16 loss, CDK4, CDK6 amplifications
Drug: Palbociclib

Other Name: Ibrance
( Cyclin-Dependent Kinases (CDK) Inhibitor )
Group 5 (CSF1R, PDGFR, VEGFR)

Participants receive sunitinib – dosage, frequency and duration per label CSF1R, PDGFR, VEGFR mutations
Drug: Sunitinib

Other Name: Sutent
Group 6 (mTOR, TSC)

Participants receive temsirolimus – dosage, frequency and duration per label mTOR, TSC mutations
Drug: Temsirolimus

Other Name: Torisel
( Mammalian Target of Rapamycin (mTOR) Inhibitor )
Group 7 (EGFR)

Participants receive erlotinib – dosage, frequency and duration per label EGFR mutations
Drug: Erlotinib

Other Name: Tarceva
( Tyrosine Kinase (TK) Inhibitor )
Group 8 (ERBB2)

Participants receive trastuzumab and pertuzumab – dosage, frequency and duration per label (ERBB2 amplifications)
Drug: Trastuzumab and Pertuzumab

Other Name: Herceptin and Perjeta
( Immunotherapy ,  Monoclonal Antibody )
Group 9 (BRAFV600E)

Participants receive vemurafenib and cobimetinib – dosage, frequency and duration per label BRAFV600E mutations
Drug: Vemurafenib and Cobimetinib

Other Name: Zelboraf and Cotellic
( Bruton’s Tyrosine Kinase (BTK) Inhibitor ) ( MEK Inhibitor )
Group 10 (PTCH1)

Participants receive vismodegib – dosage, frequency and duration per label PTCH1 deletion or inactivating mutations
Drug: Vismodegib

Other Name: Erivedge
Group 11 (KRAS, NRAS and BRAF)

Participants receive cetuximab – dosage, frequency and duration per label KRAS, NRAS and BRAF wildtype
Drug: Cetuximab

Other Name: Erbitux
( Immunotherapy ,  Monoclonal Antibody )
Group 12 (Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1)

Participants receive dasatinib- dosage, frequency and duration per label Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations
Drug: Dasatinib

Other Name: Sprycel
( Tyrosine Kinase (TK) Inhibitor )
Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF

Participants receive regorafenib- dosage, frequency and duration per label RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFRβ, RAF-1, BRAF mutations/amplifications
Drug: Regorafenib

Other Name: Stivarga
Group 14 (BRCA1/BRCA2; ATM)

Participants receive olaparib- dosage, frequency and duration per label Germline or somatic BRCA1/BRCA2 inactivating mutations; ATM mutations or deletions
Drug: Olaparib

Other Name: Lynparza
Group 15 (POLE/POLD1;high mutational load)

Participants receive pembrolizumab- dosage, frequency and duration per label Note: high mutational load defined per protocol
Drug: Pembrolizumab

Other Name: Keytruda

Learn more and find the closest trial site here: 

TUPAC Clinical Trial

To find eligible clinical trials for your myeloma, click here: Find Myeloma Clinical Trials on SparkCures

Share.

About Author

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

Leave A Reply

Please enter the correct captcha code to verify that you are human.